Report Content
Chapter 1 Methodology & Scope
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast calculation
1.4 Covid-19 impact analysis at global level
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Peptide therapeutics industry 3600 synopsis, 2018 – 2032 (USD Billion)
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Type trends
2.1.4 Application trends
2.1.5 Route of administration trends
2.1.6 Manufacturer type trends
2.1.7 Synthesis technology trends
2.1.8 Distribution channel trends
Chapter 3 Peptide Therapeutics Market Insights
3.1 Industry landscape, 2018 – 2032 (USD Billion)
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cancer
3.2.1.2 Rising incidences of metabolic & endocrinology disorders
3.2.1.3 Increasing investments in R&D of novel drugs
3.2.1.4 Technological advancement in peptide therapeutics
3.2.2 Industry pitfalls & challenges
3.2.2.1 Stringent regulatory requirements for drug approval
3.2.2.2 High cost for drug development
3.3 Growth potential analysis
3.3.1 By type
3.3.2 By application
3.3.3 By route of administration
3.3.4 By manufacturer type
3.3.5 By synthesis technology
3.3.6 By distribution channel
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Technology landscape
3.8 Porter’s analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022
Chapter 5 Peptide Therapeutics Market Estimates and Forecast, By Type, 2018-2032 (USD Billion)
5.1 Key trends, by type
5.2 Branded peptides
5.3 Generic peptides
Chapter 6 Peptide Therapeutics Market Estimates and Forecast, By Application, 2018-2032 (USD Billion)
6.1 Key trends, by application
6.2 Metabolic & endocrine disorders
6.3 Cancer
6.4 Cardiovascular disorders
6.5 Gastrointestinal disorders
6.6 Central nervous system disorders
6.7 Respiratory disorders
6.8 Pain management
6.9 Renal disorders
6.10 Dermatology
6.11 Other applications
Chapter 7 Peptide Therapeutics Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Billion)
7.1 Key trends, by route of administration
7.2 Parenteral
7.3 Oral
7.4 Other routes of administration
Chapter 8 Peptide Therapeutics Market Estimates and Forecast, By Manufacturer Type, 2018-2032 (USD Billion)
8.1 Key trends, by manufacturer type
8.2 In-house
8.3 Outsourced
Chapter 9 Peptide Therapeutics Market Estimates and Forecast, By Synthesis Technology, 2018-2032 (USD Billion)
9.1 Key trends, by synthesis technology
9.2 Liquid phase peptide synthesis (LPPS)
9.3 Solid phase peptide synthesis (SPPS)
9.4 Hybrid Technology
Chapter 10 Peptide Therapeutics Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Billion)
10.1 Key trends, by distribution channel
10.2 Hospital pharmacies
10.3 Retail pharmacies
10.4 Online pharmacies
Chapter 11 Peptide Therapeutics Market Estimates and Forecast, By Region, 2018-2032 (USD Billion)
11.1 Key trends, by region
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Switzerland
11.3.7 Rest of Europe
11.4 Asia Pacific
11.4.1 China
11.4.2 Japan
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Rest of Latin America
11.6 Middle East & Africa
11.6.1 South Africa
11.6.2 Saudi Arabia
11.6.3 Rest of Middle East & Africa
Chapter 12 Company Profiles
12.1 Pfizer, Inc.
12.2 Amgen, Inc.
12.3 Eli Lilly and Company
12.4 Sanofi SA
12.5 AstraZeneca plc
12.6 AbbVie, Inc.
12.7 GlaxoSmithKline plc
12.8 Bausch Health Companies Inc
12.9 Sun Pharmaceutical Industries Ltd.
12.10 Novo Nordisk
